Bicara Therapeutics (BCAX)

• Market cap: $920M
• 1 day: -0.65%
• 5 days: 1.02%
• 1 month: 4.22%
• 3 months: 2.07%
• 6 months: 44.83%
• Year to date: 2.56%
• 1 year: 30.13%
• 5 years: -28.24%
• 10 years: -28.24%
• Sector: Healthcare
• Industry: Biotechnology

About: Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.